IALSN presents on November 7th. of 2019 :
“Is Precision Medicine delivering on its promises?”
By: Dr. Hakan Sakul, VP and the head of Diagnostics Worldwide Research, Development & Medical at Pfizer, Inc.
Dr. Hakan Sakul has been leading Pfizer’s company-wide Diagnostics efforts since 2007, first working with the Board and Executive Leadership team to develop a strategy and then implementing it, including founding the Diagnostic Group. Under his leadership, companion diagnostics (CDx) tests have accompanied 4 Pfizer oncology drugs to global markets (3 in US and 1 in Japan), and a total of 21 global approvals for these assets. There are over a dozen additional CDx programs currently in different phases of clinical development. These CDx tests, on the market or in development, collectively span over a dozen active collaborations with diagnostics companies which he oversees.
Hakan worked in the biotech industry in human genetics and statistical genetics fields early in his career before moving to Parke-Davis Pharmaceuticals to direct human genetics, statistical genetics and pharmacogenetics programs. Following the merger of Parke-Davis with Pfizer, he has held positions of increasing responsibility at Pfizer. One of his most significant professional accomplishments was to lead Pfizer’s flagship companion diagnostics program for Xalkori ® (Crizotinib), resulting in simultaneous FDA approvals of the drug/diagnostic combination in 2011.
Hakan’s contributions to precision medicine and diagnostics have been widely recognized through both internal and external awards, frequent speaking engagements, and press coverage. He is a member of the Board of The Personalized Medicine Coalition and served on California Governor Brown’s Advisory Committee on Precision Medicine. He received his BS and MSc degrees from Ankara University in Turkey, PhD in Quantitative Genetics from the University of Minnesota and as a Rotary Foundation Scholar, he conducted postdoctoral studies at the University of California-Davis. Hakan is keenly interested in diagnostics and related medical technologies to advance Precision Medicine for the improvement of individualized healthcare and has made significant contribution in the fieldin the form of scientific articles, abstracts and book chapters.
Nov. 7, 2019
6:00- 8:00 pm.
10300 Campus Point Dr.
San Diego, CA, 92121
1st. Floor Conference Room
IALSN Annual Membership is $55
55 Membership provides the following:
One Full Year Membership Status
4 Complimentary Admission Tickets to Quarterly Scientific Events with Guest Speakers in the Healthcare/Biotech/Pharmaceutical Industries along with Networking (Food, Drink & Desert are included)
1 Complimentary Admission Ticket to Gala, plus one Additional Complimentary Admission Ticket for member’s guest
Dr. Paul Grint
Chief Executives Officer of the AmpliPhi Biosciences, Inc
President and Chief Executive Officer of Arcturus Therapeutics Ltd
John M. Beals, Ph.D.
Dr. Hakan Sakul
VP and the head of Diagnostics Worldwide Research
Founder of Abilita Bio, Inc
Podiatric foot and ankle surgeon
Peter C. Farrell
PhD, DSc, AM, Founder and Chairman of the board, ResMed
Dr. Jiwu Wang
Founder and CEO of Allele
Biotechnology & Pharma
Dr. Amir Zarrinpar, MD, PhD
Assistant Professor, Division of Gastroenterology, University of
California, San Diego
Dr Reza Shirazi
Genesis Healthcare Partners
Dr. Magda Marquet